Dear Partner,
The mission of OneOncology’s clinical team is to bring forward innovation that makes it easier for our physician partners to practice high-quality care.
In 2023, we continued to build foundational scaffolding to accomplish our mission. We used the expertise of our physicians within the disease groups to build robust clinical pathways for 25 diseases and improved the EHR interface to deliver evidenced-based options to the physician at the time of ordering (Flatiron Assist). The precision medicine program has added services to surface newly identified standards of care (Genomic Lookback) as well as possible trial options (ViTE), and the next step is to integrate this tool within the EHR (ProMPT). Our research program has added technology to both speed the launch of trials as well as ensure quality and consistency through the addition of an electronic regulatory binder and clinical trial management system (CTMS).
The last few years, we’ve invested time and money in gathering information and analytic capability to make good clinical decisions, business decisions, and partnerships with others to address unanswered clinical questions through retrospective analysis and real-world evidence. In 2023, we added expertise in addressing payor quality programs — such as MIPS, EOM, and commercial value-based care arrangements and soon, we plan to add tools that not only aid in strategy but also allow for ease of reporting.
In oncology, we all practice evidence-based medicine, but not every question can be answered by an interventional trial that compares two drugs. In fact, oncologists often face questions for which a trial cannot or will never be designed, such as the optimal sequencing of two newly approved therapies. But with retrospective studies and a richly diverse patient population, OneOncology can study outcomes from real-world evidence and glean insights for how a therapy will perform in patients that are under-represented in the clinical research. The real-world evidence generated by enabling clinical technology is helping oncologists learn from every patient experience, whether they were enrolled in a clinical trial or not.
The last few years, we’ve invested time and money in gathering information and analytic capability to make good clinical decisions, business decisions, and now partner with others to address unanswered clinical questions through retrospective analysis and real-world evidence.
Dr. Ian Flinn Appointed Chief Scientific Officer
Ian Flinn, MD, PhD has three decades of excellence in clinical research, with most of his experience spent in community oncology, where he has helped develop many important advances to treat hematological malignancies and has also proven that treatment changing research must include community oncology.
A consistent theme through Dr. Flinn’s research is determining how to make clinical trials practical and pragmatic. A physician who still maintains a busy practice, Dr. Flinn understands the importance that the right trial can have for the individual patient. However, to really enhance OneOncology partner practices’ ability to do research, we must provide additional services that make it easier for a busy clinician to identify the right option. We believe that centralized clinical services such as patient pre-screening for trials, rapid identification and opening of new trials in an accelerated manner, and in the future, even data entry and quality assurance will be pivotal to growth of individual practices’ research offerings and OneR. The increased flexibility that these approaches offer makes it possible to increase our trial offerings, ensure that trials better reflect our patient populations, and ultimately increase the number of patients who find a trial that is right for them.
Looking Forward
I’m extremely excited about the year ahead. In 2023 we built a strong foundation of clinical tools to help our physicians continue to practice high-quality care. And in 2024, our focus is now deploying these tools at scale within practice partners’ workflows, making it easier to care for patients.
Sincerely,
Davey Daniel, MD
Chief Medical Officer
OneOncology